Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

James Pride

Internal Medicine Arlington Heights, IL Medical Doctor

NPI 1831138528 CMS profile 264930

3405 N Arlington Heights Rd, Arlington Heights, IL 60004

Open in the dashboard

General payments

$6,639

367 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, James Pride of Arlington Heights, IL is reported in the CMS Open Payments database as having received $6,639 across 367 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 91st percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $235 11
2024 General $1,088 61
2023 General $940 46
2022 General $1,262 63
2021 General $1,153 62
2020 General $802 46
2019 General $1,158 78

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • James Pride
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to James Pride were reported at $235. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year James Pride Internal Medicine median Middle half National median
2019 $1,158 $159 $48–$570 $163
2020 $802 $119 $33–$402 $114
2021 $1,153 $135 $37–$521 $132
2022 $1,262 $141 $42–$496 $149
2023 $940 $149 $45–$519 $160
2024 $1,088 $154 $47–$537 $164
2025 $235 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novo Nordisk Inc $1,681 87 payments
  2. AbbVie, Inc. $1,079 50 payments
  3. Amgen Inc. $680 45 payments
  4. Pfizer Inc. $617 29 payments
  5. Merck Sharp & Dohme Corporation $381 36 payments
  6. GlaxoSmithKline, LLC. $265 18 payments
  7. AstraZeneca Pharmaceuticals LP $200 14 payments
  8. Bayer HealthCare Pharmaceuticals Inc. $183 8 payments
  9. Lilly USA, LLC $178 9 payments
  10. E.R. Squibb & Sons, L.L.C. $104 6 payments
  11. Other $1,271 65 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,619 366 payments
  2. Education $20 1 payment
Products named General payments · program years 2019–2025
  1. Ozempic $1,482 76 payments
  2. RYBELSUS $1,254 62 payments
  3. Prolia $413 26 payments
  4. EVENITY $359 23 payments
  5. UBRELVY $358 15 payments
  6. Repatha $303 21 payments
  7. VRAYLAR $273 12 payments
  8. Otezla $266 19 payments
  9. PREVNAR 20 $242 9 payments
  10. COMIRNATY $242 9 payments
  11. Other $5,075 314 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 81 drugs

Part D claims

5,662

Median for Internal Medicine: 777

Drug cost

$332,001

Median for Internal Medicine: $73,373

Branded share of claims

11.8%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 63 $87,473
Eliquis Apixaban Brand 52 $63,915
Rybelsus Semaglutide Brand 21 $35,347
Creon Lipase/Protease/Amylase Brand 13 $22,796
Farxiga Dapagliflozin Propanediol Brand 13 $21,834
Jardiance Empagliflozin Brand 23 $18,971
Januvia Sitagliptin Phosphate Brand 13 $10,157
Atorvastatin Calcium Generic 961 $8,881
Shingrix Varicella-Zoster Ge/As01b/Pf Brand 23 $5,069
Losartan Potassium Generic 410 $4,002

The 10 drugs with the highest cost, of 81 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 55 billing codes

Paid by Medicare

$243,335

Of which drugs: $45,398

Medicare patients

443

Average age 76

Services billed

3,921

194 women, 249 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 73%
Arthritis 39%
Ischemic heart disease 28%
Diabetes 21%
Osteoporosis 21%
Cancer 20%
Atrial fibrillation 19%
Chronic kidney disease 16%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Pcv20 vaccine im 90677 Office 123 123 $35,558
Sarscv2 vac 30mcg trs-suc im 91320 Office 50 50 $6,924
Vaccine for influenza for injection into muscle 90653 Office 68 68 $2,666

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 30 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VRAYLAR
  • AbbVie, Inc. $166
$166 — —
RYBELSUS
  • Novo Nordisk Inc $91
$91 21 —
Ozempic
  • Novo Nordisk Inc $91
$91 63 —
SPRAVATO
  • Janssen Pharmaceuticals, Inc $54
$54 — —
Otezla
  • Amgen Inc. $52
$52 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 30 with Patron

Records

367 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record